Chwilio Deddfwriaeth

Chwiliad Uwch

Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC)

Help about what version

Pa Fersiwn

Help about UK-EU Regulation

Deddfwriaeth yn deillio o’r UE

Pan adawodd y DU yr UE, cyhoeddodd legislation.gov.uk ddeddfwriaeth yr UE a gyhoeddwyd gan yr UE hyd at ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11.00 p.m.). Ar legislation.gov.uk, mae'r eitemau hyn o ddeddfwriaeth yn cael eu diweddaru'n gyson ag unrhyw ddiwygiadau a wnaed gan y DU ers hynny.

Close

Mae'r eitem hon o ddeddfwriaeth yn tarddu o'r UE

Mae legislation.gov.uk yn cyhoeddi fersiwn y DU. Mae EUR-Lex yn cyhoeddi fersiwn yr UE. Mae Archif Gwe Ymadael â’r UE yn rhoi cipolwg ar fersiwn EUR-Lex o ddiwrnod cwblhau’r cyfnod gweithredu (31 Rhagfyr 2020 11.00 p.m.).

Changes to legislation:

There are currently no known outstanding effects by UK legislation for Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC). Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

  1. Introductory Text

  2. Article 1.The technical specifications set out in the Annex to this...

  3. Article 2.This Decision is addressed to the Member States.

    1. ANNEX

      COMMON TECHNICAL SPECIFICATIONS (CTS) FOR IN VITRO DIAGNOSTIC MEDICAL DEVICES

      1. 1. SCOPE

      2. 2. DEFINITIONS AND TERMS

        1. (Diagnostic) sensitivity

        2. True positive

        3. False negative

        4. (Diagnostic) specificity

        5. False positive

        6. True negative

        7. Analytical sensitivity

        8. Analytical specificity

        9. Nucleic acid amplification techniques (NAT)

        10. Rapid test

        11. Robustness

        12. Whole system failure rate

        13. Confirmation assay

        14. Virus typing assay

        15. Sero-conversion HIV samples

        16. Early sero-conversion HIV samples

      3. 3. COMMON TECHNICAL SPECIFICATIONS (CTS) FOR PRODUCTS REFERRED TO IN ANNEX...

        1. 3.1. CTS for performance evaluation of reagents and reagent products for...

          1. General principles

            1. 3.1.1. Devices which detect virus infections shall meet the requirements for...

            2. 3.1.2. Devices intended by the manufacturer for testing body fluids other...

            3. 3.1.3. Devices intended by the manufacturer for self-test, i.e. home use,...

            4. 3.1.4. All performance evaluations shall be carried out in direct comparison...

            5. 3.1.5. If discrepant test results are identified as part of an...

            6. 3.1.6. Performance evaluations shall be performed on a population equivalent to...

            7. 3.1.7. Positive specimens used in the performance evaluation shall be selected...

            8. 3.1.8. Sensitivity with true positives and sero-conversion samples shall be evaluated...

            9. 3.1.9. Performance evaluation of screening assays shall include 25 positive (if...

            10. 3.1.10. Negative specimens used in a performance evaluation shall be defined...

            11. 3.1.11. For performance evaluations for screening assays (Table 1) blood donor...

            12. 3.1.12. Devices shall have a specificity of at least 99,5 % on...

            13. 3.1.13. Devices shall be evaluated to establish the effect of potential...

            14. 3.1.14. For devices intended by the manufacturer to be used with...

            15. 3.1.15. For devices intended for use with plasma the performance evaluation...

            16. 3.1.16. As part of the required risk analysis the whole system...

            17. 3.1.17. If a new in vitro diagnostic medical device belonging to...

        2. 3.2. Additional requirements for HIV and HCV antigen and antibody combined...

          1. 3.2.1. HIV antigen and antibody combined tests intended for the detection...

          2. 3.2.2. Hepatitis C virus (HCV) antigen and antibody combined tests intended...

        3. 3.3. Additional requirements for nucleic acid amplification techniques (NAT)

          1. 3.3.1. For target sequence amplification assays, a functionality control for each...

          2. 3.3.2. The analytical sensitivity or detection limit for NAT assays shall...

          3. 3.3.2a. Qualitative HIV NAT assays intended to be used to detect...

          4. 3.3.2b. Qualitative HIV NAT assays, other than virus typing assays, shall...

          5. 3.3.3. Genotype detection shall be demonstrated by appropriate primer or probe...

          6. 3.3.4. Results of quantitative NAT assays shall be traceable to international...

          7. 3.3.5. NAT assays may be used to detect virus in antibody...

          8. 3.3.6. For investigation of potential carry-over, at least five runs with...

          9. 3.3.7. The whole system failure rate leading to false-negative results shall...

        4. 3.4. CTS for the manufacturer’s release testing of reagents and reagent...

          1. 3.4.1. The manufacturer’s release testing criteria shall ensure that every batch...

          2. 3.4.2. The manufacturer’s batch release testing for screening assays shall include...

        5. 3.5. CTS for performance evaluation of reagents and reagent products for...

          1. 3.5.1. All performance evaluations shall be carried out in direct comparison...

          2. 3.5.2. If discrepant test results are identified as part of an...

          3. 3.5.3. Performance evaluations shall be performed on a population equivalent to...

          4. 3.5.4. Positive specimens used in the performance evaluation shall be selected...

          5. 3.5.5. Devices shall be evaluated to establish the effect of potential...

          6. 3.5.6. For devices intended for use with plasma the performance evaluation...

        6. 3.6. CTS for the manufacturer’s release testing of reagents and reagent...

          1. 3.6.1. The manufacturer’s release testing criteria shall ensure that every batch...

          2. 3.6.2. Requirements for manufacturers batch release testing are outlined in Table...

        7. 3.7. CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening...

        8. Acceptance criteria:

        9. Qualifications:

        10. Table 10 Batch release criteria for reagents and reagent products to determine...Specificity testing requirements on each reagent 1. Test reagents Only...

          1. 1. Test reagents

            1. Acceptance criteria:

          2. 2. Control materials (red cells)

Yn ôl i’r brig

Options/Cymorth

Print Options

Close

Mae deddfwriaeth ar gael mewn fersiynau gwahanol:

Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.

Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Dewisiadau Agor

Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd

Close

Rhagor o Adnoddau

Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted version that was used for the EU Official Journal
  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • pob fformat o’r holl ddogfennau cysylltiedig
  • slipiau cywiro
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Close

Llinell Amser Newidiadau

Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.

Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.

Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.

Close

Rhagor o Adnoddau

Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted fersiwn a ddefnyddiwyd am y copi print
  • slipiau cywiro

liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys

  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill

Mae'r data ar y dudalen hon ar gael yn y fformatau data amgen a restrir: